Targeting the intestinal L-cell for obesity and type 2 diabetes treatment

Expert Review of Endocrinology and Metabolism

Volumn 9, Issue 1, 2014, Pages 61-72

  Albrechtsen, Nicolai Jacob Wewer ^a   Kuhre, Rune Ehrenreich ^a   Deacon, Carolyn F ^a   Holst, Jens Juul ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

appetite regulation; gut hormones; gut brain axis; L cell; obesity

Indexed keywords

AMINO ACID; BILE ACID; CARBOHYDRATE; CHOLECYSTOKININ; GLICENTIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; HORMONE; LIPID; NEUROTENSIN; OXYNTOMODULIN; PEPTIDE; PEPTIDE YY; PROGLUCAGON; PROTEIN;

APPETITE; BLOOD BRAIN BARRIER; BRAIN; CELL ACTIVATION; CELLULAR SECRETION; FOOD INTAKE; HUMAN; HYPOTHALAMUS; INTESTINAL L CELL; INTESTINE; L CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT; OBESITY; PRIORITY JOURNAL; REVIEW; VAGUS NERVE;

EID: 84893138518     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/17446651.2014.862152     Document Type: Review

References (132)

1. Malik VS, Willett WC, Hu FB. Global obesity: Trends, risk factors and policy implications. Nat. Rev. Endocrinol. 9(1), 13-27 (2013
2. Ryan D, Bray G. Pharmacologic treatment options for obesity: What is old is new again. Curr. Hypertens. Rep. 15(3), 182-189 (2013
3. Diana R, Raj P, Stephanie KL, Cintia C, David CWL. Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. BMJ 335, 1194 (2007
4. Kirk SFL, Penney TL, McHugh TL, Sharma AM. Effective weight management practice: A review of the lifestyle intervention evidence. Int. J. Obes. 36(2), 178-185 (2012
5. Colquitt JL, Picot J, Loveman E, Clegg AJ. Surgery for obesity. Cochrane Database Syst. Rev. (2), CD003641 (2009
6. DeFronzo RA, Abdul-Ghani MA. Preservation of beta-cell function: The key to diabetes prevention. J. Clin. Endocrinol. Metab. 96(8), 2354-2366 (2011
7. DeFronzo RA. Overview of newer agents: Where treatment is going. Am. J. Med. 123(3 Suppl.), S38-S48 (2010
8. Grunberger G. Novel therapies for management of type 2 diabetes mellitus part 2 - Addressing the incretin defect in clinical setting in 2013. J. Diabetes 5(3), 241-253 (2013
9. Egerod KL, Engelstoft MS, Grunddal KV et al. A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin. Endocrinology 153(12), 5782-5795 (2012
10. Habib AM, Richards P, Rogers GJ, Reimann F, Gribble FM. Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells. Diabetologia 56(6), 1413-1416 (2013
11. Habib AM, Richards P, Cairns LS et al. Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology 153(7), 3054-3065 (2012
12. Mortensen K, Christensen LL, Holst JJ, Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul. Pep. 114(2G), 189-196 (2003
13. Holst JJ. Incretin hormones and the satiation signal. Int. J. Obes. 37(9), 1161-1168 (2013
14. Holst JJ. The physiology of glucagon-like peptide 1. Physiol. Rev. 87(4), 1409-1439 (2007
15. Baldissera FG, Holst JJ, Knuhtsen S, Hilsted L, Nielsen OV. Oxyntomodulin (glicentin-(33-69)): Pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul. Pept. 21(1-2), 151-166 (1988
16. Pedersen J, Ugleholdt RK, Jorgensen SM et al. Glucose metabolism is altered after loss of L cells and alfa cells but not influenced by loss of K cells. Am. J. Physio. Endocrinol. Metab. 304(1), e60-e73 (2013
17. Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J. Compar. Physiol. Psychol. 84(3), 488-495 (1973
18. Suzuki K, Jayasena CN, Bloom SR. Obesity and appetite control. Exp. Diabetes Res. 2012, 824305 (2012
19. Amitani M, Asakawa A, Amitani H, Inui A. The role of leptin in the control of insulin-glucose axis. Front. Neurosci. 7, 51 (2013
20. Suzuki K, Simpson KA, Minnion JS, Shillito JC, Bloom SR. The role of gut hormones and the hypothalamus in appetite regulation. Endocr. J. 57(5), 359-372 (2010
21. Sumithran P, Proietto J. The defence of body weight: A physiological basis for weight regain after weight loss. Clin. Sci. (Lond.) 124(4), 231-241 (2013
22. Chaudhri OB, Salem V, Murphy KG, Bloom SR. Gastrointestinal satiety signals. Ann. Rev. Physiol. 70, 239-255 (2008
23. Wang C, Bomberg E, Billington CJ, Levine AS, Kotz CM. Brain-derived neurotrophic factor (BDNF) in the hypothalamic ventromedial nucleus increases energy expenditure. Brain Res. 1336, 66-77 (2010
24. Jo YH, Chua S Jr. Transcription factors in the development of medial hypothalamic structures. Am. J. Physiol. Endocrinol. Metab. 297(3), e563-e567 (2009
25. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. Nature 444(7121), 854-859 (2006
26. Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 Neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 153(2), 647-658 (2012
27. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9- 36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140(11), 5356-5363 (1999
28. Hjollund KR, Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs. Diabetologia 54(8), 2206-2208 (2011
29. Ruttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 150(3), 1174-1181 (2009
30. Abbott CR, Monteiro M, Small CJ et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res. 1044(1), 127-131 (2005
31. Bucinskaite V, Tolessa T, Pedersen J et al. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterol. Motil. 21(9), 978-e78 (2009
32. Moran TH, Baldessarini AR, Salorio CF, Lowery T, Schwartz GJ. Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. Am. J. Physiol. 272(4), R1245-R1251 (1997
33. Koda S, Date Y, Murakami N et al. The role of the vagal nerve in peripheral PYY3-36 induced feeding reduction in rats. Endocrinology 146(5), 2369-2375 (2005
34. Plamboeck A, Veedfald S, Deacon CF et al. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am. J. Physiol. Gastrointest. Liver Physiol. 304(12), G1117-G1127 (2013
35. Nakagawa A, Satake H, Nakabayashi H et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton. Neurosci. 110(1), 36-43 (2004
36. Vahl TP, Tauchi M, Durler TS et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148(10), 4965-4973 (2007
37. Liu WY, Wang ZB, Zhang LC, Wei X, Li L. Tight junction in blood-brain barrier: An overview of structure, regulation, and regulator substances. CNS Neurosci. Ther. 18(8), 609-615 (2012
38. Fry M, Ferguson AV. The sensory circumventricular organs: Brain targets for circulating signals controlling ingestive behavior. Physiol. Behav. 91(4), 413-423 (2007
39. Orskov C, Poulsen SS, Moller M, Holst JJ Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45(6), 832-835 (1996
40. Kastin A, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 18(1-2), 7-14 (2002
41. Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 150(4), 1680-1687 (2009
42. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101(3), 515-520 (1998
43. Degen L, Oesch S, Casanova M et al. Effect of peptide YY 3-36 on food intake in humans. Gastroenterology 129(5), 1430-1436 (2005
44. Lieverse RJ, Jansen JB, Masclee AA, Lamers CB. Satiety effects of a physiological dose of cholecystokinin in humans. Gut 36(2), 176-179 (1995
45. Baraboi ED, Smith P, Ferguson AV, Richard D. Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298(4), R1098-R1110 (2010
46. le Roux CW, Welbourn R, Werling M et al. Gut hormones as mediators of appetite and weight loss after roux-en-Y gastric bypass. Ann. Surg. 246(5), 780-785 (2007
47. Dirksen C, Jorgensen NB, Bojsen-Moller KN et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int. J. Obes. (Lond.) doi:10.1038/ijo.2013.15 (2013) (Epub ahead of print
48. Rehfeld JF, Agersnap M. Unsulfated cholecystokinin: An overlooked hormone? Regul. Pept. 173(1-3), 1-5 (2012
49. Wank SA, Pisegna JR, de WA. Brain and gastrointestinal cholecystokinin receptor family: Structure and functional expression. Proc. Natl Acad. Sci. USA 89(18), 8691-8695 (1992
50. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41(3), 271-278 (1998
51. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80(3), 952-957 (1995
52. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 63(2), 492-498 (1986
53. Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 34(Suppl. 2), S251-S257 (2011
54. Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51(12), 2263-2270 (2008
55. Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 59(7), 1765-1770 (2010
56. Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology 132(6), 2131-2157 (2007
57. Astrup A, Rössner S, Van Gaal L et al. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet 374(9701), 1606-1616 (2007
58. Astrup A, Carraro R, Finer N et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int. J. Obes. 36(6), 843-854 (2012
59. Vrang N, Larsen PJ. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides. Prog. Neurobiol. 92(3), 442-462 (2010
60. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, and clinical implications. Am. J. Med. 124(1 Suppl.), S3-S18 (2011
61. Davidson JA. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve. Clin. J. Med. 76(Suppl. 5), S28-S38 (2009
62. Dicker D. DPP-4 inhibitors: Impact on glycemic control and cardiovascular risk factors. Diabetes Care 34(Suppl. 2), S276-S278 (2011
63. Holst JJ. Glucagon and glucagon-like peptides 1 and 2. Results Probl. Cell Differ. 50, 121-135 (2010
64. Kissow H, Viby NE, Hartmann B et al. Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine. Cancer Chemother. Pharmacol. 70(1), 39-48 (2012
65. Askov-Hansen C, Jeppesen PB, Lund P, Hartmann B, Holst JJ, Henriksen DB. Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure. Regul. Pept. 181, 4-8 (2013
66. Tang-Christensen M, Larsen PJ, Thulesen J, Romer J, Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat. Med. 6(7), 802-807 (2000
67. Sorensen LB, Flint A, Raben A, Hartmann B, Holst JJ, Astrup A. No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int. J. Obes. Relat. Metab. Disord. 27(4), 450-456 (2003
68. Schmidt PT, Näslund E, Grybäck P et al. Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul. Pep. 116(1-3), 21-25 (2003
69. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89(5), 1070-1077 (1985
70. Simpson K, Parker J, Plumer J, Bloom S. CCK, PYY and PP: The control of energy balance. Handb. Exp. Pharmacol. (209), 209-230 (2012
71. Lluis F, Fujimura M, Gomez G, Salva JA, Greeley GH Jr, Thompson JC. [Cellular localization, half-life, and secretion of peptide YY]. Rev. Esp. Fisiol. 45(4), 377-384 (1989
72. Rudnicki M, Kuvshinoff BW, McFadden DW. Extrinsic neural contribution to ileal peptide YY (PYY) release. J. Surg. Res. 52(6), 591-595 (1992
73. Batterham RL, Cowley MA, Small CJ et al. Physiology: Does gut hormone PYY3-36 decrease food intake in rodents? (reply). Nature 430, 6996 (2004
74. Batterham RL, Cohen MA, Ellis SM et al. Inhibition of food intake in obese subjects by peptide YY3. N. Engl. J. Med. 349(10), 941-948 (2003
75. De SA, Bloom SR. Gut hormones and appetite control: A focus on PYY and GLP-1 as therapeutic targets in obesity. Gut Liver 6(1), 10-20 (2012
76. Ghamari-Langroudi M, Colmers WF, Cone RD. PYY3-36 inhibits the action potential firing activity of POMC neurons of arcuate nucleus through postsynaptic Y2 receptors. Cell Metab. 2(3), 191-199 (2005
77. Holst JJ. Enteroglucagon. Ann. Rev. Physiol. 59, 257-271 (1997
78. Read N, French S, Cunningham K. The role of the gut in regulating food intake in man. Nutr. Rev. 52(1), 1-10 (1994
79. Holst JJ. Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochem. J. 207(3), 381-388 (1982
80. Bataille D, Gespach C, Tatemoto K et al. Bioactive enteroglucagon (oxyntomodulin): Present knowledge on its chemical structure and its biological activities. Peptides 2(Suppl. 2), 41-44 (1981
81. Pocai A. Unraveling Oxyntomodulin, GLP-1's enigmatic brother. J. Endocrinology 215(3), 335-346 (2012
82. Wynne K, Bloom SR. The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control. Nat. Clin. Pract. Endocrinol. Metab. 2(11), 612-620 (2006
83. Jarrousse C, Bataille D, Jeanrenaud B. A pure enteroglucagon, oxyntomodulin (glucagon 37), stimulates insulin release in perfused rat pancreas. Endocrinology 115(1), 102-105 (1984
84. Wynne K, Field BC, Bloom SR. The mechanism of action for oxyntomodulin in the regulation of obesity. Curr. Opin. Investig. Drugs 11(10), 1151-1157 (2010
85. Wynne K, Park AJ, Small CJ et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: A randomised controlled trial. Int. J. Obes. (Lond.) 30(12), 1729-1736 (2006
86. Dakin CL, Small CJ, Batterham RL et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145(6), 2687-2695 (2004
87. Dakin CL, Gunn I, Small CJ et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology 142(10), 4244-4250 (2001
88. Kosinski JR, Hubert J, Carrington PE et al. The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin. Obes. (Silver Spring) 20(8), 1566-1571(2012
89. Pocai A, Carrington PE, Adams JR et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58(10), 2258-2266 (2009
90. Druce MR, Bloom SR. Oxyntomodulin: A novel potential treatment for obesity. Treat. Endocrinol. 5(5), 265-272 (2006
91. Lopez LC, Frazier ML, Su CJ, Kumar A, Saunders GF. Mammalian pancreatic preproglucagon contains three glucagon-related peptides. Proc. Natl Acad. Sci.USA 80(18), 5485-5489 (1983
92. Blache P, Kervran A, Bataille D. Oxyntomodulin and glicentin: Brain-gut peptides in the rat. Endocrinology 123(6), 2782-2787 (1988
93. Tomita R, Igarashi S, Tanjoh K, Fujisaki S. Role of recombinant human glicentin in the normal human jejunum: An in vitro study. Hepatogastroenterology 52(65), 1459-1462 (2005
94. Mustain WC, Rychahou PG, Evers BM. The role of neurotensin in physiologic and pathologic processes. Curr. Opin. Endocrinol. Diabetes Obes. 18(1), 75-82 (2011
95. Jacobsen L, Madsen P, Jacobsen C, Nielsen MS, Gliemann J, Petersen CM. Activation and functional characterization of the mosaic receptor SorLA/LR11. J. Biol. Chem. 276(25), 22788-22796 (2001
96. Christ-Crain M, Stoeckli R, Ernst A et al Effect of gastric bypass and gastric banding on neurotensin levels in morbidly obese patients. J. Clin. Endocrinol. Metab. 91(9), 3544-3547 (2006
97. Eissele R, Goke R, Willemer S et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur. J. Clin. Invest. 22(4), 283-291 (1992
98. de Bruine AP, Dinjens WN, Pijls MM et al. NCI-H716 cells as a model for endocrine differentiation in colorectal cancer. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 62(5), 311-320 (1992
99. Drucker DJ, Jin T, Asa SL, Young TA, Brubaker PL. Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. Mol. Endocrinol. 8(12), 1646-1655 (1994
100. Rindi G, Grant SG, Yiangou Y et al. Development of neuroendocrine tumors in the gastrointestinal tract of transgenic mice. Heterogeneity of hormone expression. Am. J. Pathol. 136(6), 1349-1363 (1990
101. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. glucose sensing in L cells: A primary cell study. Cell Metab. 8(6), 532-539 (2008
102. Jacobsen SH, Olesen SC, Dirksen C et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes. Surg. 22(7), 1084-1096 (2012
103. Gorboulev V, Schürmann A, Vallon V et al. Na+-d-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61(1), 187-196 (2012
104. Parker HE, Adriaenssens A, Rogers G et al. Predominant role of active versus facilitative glucose transport for glucagon-like peptide- 1 secretion. Diabetologia 55(9), 2445-2455 (2012
105. Diakogiannaki E, Gribble FM, Reimann F. Nutrient detection by incretin hormone secreting cells. Physiol. Behav. 106(3), 387-393 (2012
106. Yoder SM, Yang Q, Kindel TL, Tso P. Stimulation of incretin secretion by dietary lipid: Is it dose dependent? Am. J. Physiol. Gastrointest. Liver Physiol. 297(2), G299-G305 (2009
107. Murphy MC, Isherwood SG, Sethi S et al. Postprandial lipid and hormone responses to meals of varying fat contents: Modulatory role of lipoprotein lipase? Eur. J. Clin. Nutr. 49(8), 578-588 (1995
108. Engelstoft MS, Egerod KL, Holst B, Schwartz TW. A gut feeling for obesity: 7TM sensors on enteroendocrine cells. Cell Metab. 8(6), 447-449 (2008
109. Chu ZL, Carroll C, Alfonso J et al. A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide- 1 and glucose-dependent insulinotropic peptide release. Endocrinol. 149(5), 2038-2047 (2008
110. Rodriguez de Fonseca F, Navarro M, Gomez R et al. An anorexic lipid mediator regulated by feeding. Nature 414(6860), 209-212 (2001
111. Hansen KB, Rosenkilde MM, Knop FK et al. 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. J. Clin. Endocrinol. Metab. 96(9), E1409-E1417 (2011
112. Overton HA, Babbs AJ, Doel SM et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 3(3), 167-175 (2006
113. Parker HE, Wallis K, le Roux CW, Wong KY, Reimann F, Gribble FM. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br. J. Pharmacol. 165(2), 414-423 (2012
114. Hansen M, Sonne DP, Mikkelsen KH, Gluud LL, Vilsböll T, Knop FK. Effect of bile acid sequestrants on glycaemic control: Protocol for a systematic review with meta-analysis of randomised controlled trials. BMJ Open 2(6) (2012
115. Reimer RA. Meat hydrolysate and essential amino acid-induced glucagon-like peptide-1 secretion, in the human NCI-H716 enteroendocrine cell line, is regulated by extracellular signal-regulated kinase1/2 and p38 mitogen-activated protein kinases. J. Endocrinol. 191(1), 159-170 (2006
116. Cordier-Bussat M, Bernard C, Levenez F et al. Peptones stimulate both the secretion of the incretin hormone glucagon-like peptide 1 and the transcription of the proglucagon gene. Diabetes 47(7), 1038-1045 (1998
117. Reimann F. Molecular mechanisms underlying nutrient detection by incretin-secreting cells. Int. Dairy J. 20(4), 236-242 (2010
118. Reimann F, Williams L, Silva Xavier G, Rutter GA, Gribble FM. Glutamine potently stimulates glucagon-like peptide- 1 secretion from GLUTag cells. Diabetologia 47(9), 1592-1601 (2004
119. Greenfield JR, Farooqi IS, Keogh JM et al. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am. J. Clin. Nutr. 89(1), 106-113 (2009
120. Zambrowicz B, Freiman J, Brown PM et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin. Pharmacol. Ther. 92(2), 158-169 (2012
121. Zambrowicz B, Ding ZM, Ogbaa I et al. Effects of LX4211, a dual SGLT1/ SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin. Ther. 35(3), 273-285 (2013
122. Powell DR, Smith M, Greer J et al. LX4211 Increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)- mediated absorption of intestinal glucose. J. Pharmacol. Exp. Ther. 345(2), 250-259 (2013
123. Shibazaki T, Tomae M, Ishikawa-Takemura Y et al. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J. Pharmacol. Exp. Ther. 342(2), 288-296 (2012
124. Katz LB, Gambale JJ, Rothenberg PL et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects. Clin. Pharmacol. Ther. 90(5), 685-692 (2011
125. Flock G, Holland D, Seino Y, Drucker DJ. GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. Endocrinology 152(2), 374-383 (2011
126. Thomas C, Gioiello A, Noriega L et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10(3), 167-177 (2009
127. Shang Q, Saumoy M, Holst JJ, Salen G, Xu G. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am. J. Physiol. Gastrointest. Liver Physiol. 298(3), G419-G424 (2010
128. Adrian TE, Gariballa S, Parekh KA et al. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia 55(9), 2343-2347 (2012
129. Xiong Y, Swaminath G, Cao Q et al. Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1. Mol. Cell. Endocrinol. 369(1-2), 119-129 (2013
130. Luo J, Swaminath G, Brown SP et al. A Potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS ONE 7(10), e46300 (2012
131. Ahlkvist L, Vikman J, Pacini G, Ahren B. Synergism by individual macronutrients explains the marked early GLP-1 and islet hormone responses to mixed meal challenge in mice. Regul. Pep. 178(1-3), 29-35 (2012
132. Migoya EM, Bergeron R, Miller JL et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin. Pharmacol. Ther. 88(6), 801-808 (2010